AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

09-30 Earnings release - Q2 2026

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 00:57:29 29/05/2026 HKT			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-11	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	56.17M 64.85M 52.36M 48.16M 90.92M 6.17B 91.93M 615M 241M 3.09B 244M 238M 10.22B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	56.17M 64.85M 52.36M 48.16M 90.92M 6.17B 91.93M 615M 241M 3.09B 244M 238M 10.22B	EV / Sales 2026 *	46.8x	EV / Sales 2027 *	43.2x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-11	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-07	AB Science S.A. Announces Board Changes	CI
07-07	AB Science S.A. Announces CEO Changes	CI
07-03	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib

08-05	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL

AB Science Stock OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-13	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
07-13	Wall Street ne chômera pas le 14 juillet
07-11	AB Science rationalise son portefeuille et se recentre sur deux molécules
07-10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	3.84
5 years	0	17.1
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	59.71M
MERCK & CO., INC.	+0.31%	-1.27%	+59.30%	+21.31%	316B
MERCK KGAA	-0.92%	-0.07%	+34.38%	-9.40%	73.28B
HALOZYME THERAPEUTICS, INC.	-0.05%	-0.11%	+36.80%	+98.02%	9.87B
KYOWA KIRIN CO., LTD.	+0.10%	-7.59%	-4.29%	-6.23%	8.15B
SK BIOPHARMACEUTICALS CO., LTD.	+2.76%	+3.14%	-14.67%	-14.85%	4.38B
YUHAN CORPORATION	+0.40%	+6.22%	-33.30%	+7.29%	3.91B
BETTA PHARMACEUTICALS CO., LTD.	+2.46%	+2.51%	-14.87%	+21.19%	3.62B
SUPERNUS PHARMACEUTICALS, INC.	+9.36%	+1.31%	+25.71%	+46.29%	2.51B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.19%	+6.42%	-2.77%	-3.33%	2.24B
Average	+1.43%	-0.50%	+9.59%	+17.81%	47.12B
Weighted average by Cap.	+0.22%	-1.99%	+50.47%	+16.78%

	2026 *	2027 *
Net sales	1.2M 1.39M 1.12M 1.03M 1.94M 132M 1.96M 13.15M 5.16M 65.92M 5.2M 5.09M 218M	1.3M 1.5M 1.21M 1.11M 2.1M 143M 2.13M 14.24M 5.59M 71.41M 5.64M 5.51M 237M
Net income	-	-
Net Debt	-	-